4,901 trials
Malaria
Primary: Relative Bioavailability (Frel) of the Maximum Observed Plasma Concentration (Cmax) of the PQP Dispersible Granule Compared to the PQP Hard Tablet in the Fasted State…
Malaria · Malaria,Falciparum
Primary: Number of Serious Adverse Events and Grade 3 Adverse Events — 0; 0; 0; 0 adverse events
Prostate Cancer Recurrent · Prostate Cancer · Prostate Adenocarcinoma
Primary: Number of Participants With Dose-limiting Toxicities (Treatment-related Adverse Events) as Assessed by the CTCAE v5.0 — 0; 0; 0 Participants
Kaposi Sarcoma · HIV Infections
Primary: To Determine the Safety of Escalating Doses of Tc 99m Tilmanocept in HIV Subjects With Biopsy-confirmed KS. — 0; 0; 0 Safety Signals
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab Administered by PFS and AI — 20.0; 23.5 micrograms per milliliter (μg/mL)
Influenza · Seasonal Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 4; 12; 9; 8 Participants
Schizophrenia
Primary: Number of Participants Who Experience ≥1 Adverse Event (AE) in Period 1 — 1; 4; 2 Participants
Stage IV NSCLC
Primary: Number of Participants With Adverse Events and/or Dose Limiting Toxicities of Sintilimab in Combination With SBRT and LDRT — 0; 5; 1; 6 Participants
Advanced Solid Tumor
Primary: Determine Disease Response Following 2 or 3 CPX-POM Treatment Cycles by Assessing the Complete and Partial Pathologic Response Rate at the Time of Radical Cystectomy…
Thyroid Carcinoma · Thyroid Cancer · Thyroid Cancer, Follicular
Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Infections
Primary: Cefazolin Plasma Concentration Following Infusion — 491; 117; 99.7; 57.9 ug/mL
Healthy
Primary: Maximum Measured Concentration of BI 1358894 in Plasma (Cmax) — 497; 556; 484; 604 Nanomole (nmol) / Litre (L)
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 3; 3; 4; 3 Participants
Healthy
Primary: Part 1: Mass Balance and Recoveries of [14C] BI 1358894 Total Radioactivity in Urine and Faeces After Single Oral Dose (Fe0-tz) — 85.8 Percentage of administered dose
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 0; 1 Participants